Drug profile · INN
oxymetazoline hydrochloride
UPNEEQ
oxymetazoline hydrochloride (UPNEEQ) is a adrenergic receptor alpha agonist. Route of administration: ophthalmic. Current US regulatory status: approved.
Drug details — oxymetazoline hydrochloride
- US status
- approved
- Class
- —
- Route
- OPHTHALMIC
- Patents
- 1
- Programs
- 2
- Data quality
- 0.84
Quick answer
oxymetazoline hydrochloride (UPNEEQ) is a adrenergic receptor alpha agonist. Route of administration: ophthalmic. Current US regulatory status: approved.
Key facts
Mechanism of action
Adrenergic receptor alpha agonist
Primary target: Adrenergic receptor alpha
Approval history
| Authority | Status | Date |
|---|---|---|
| FDA | approved | — |
Pipeline programs
Related & competitor drugs
Related patents
Frequently asked questions
What is oxymetazoline hydrochloride?
oxymetazoline hydrochloride (UPNEEQ) is a adrenergic receptor alpha agonist. Route of administration: ophthalmic. Current US regulatory status: approved.
What is the brand name for oxymetazoline hydrochloride?
UPNEEQ is a marketed brand name for oxymetazoline hydrochloride. Check FDA Drugs@FDA for the current US label holder and prescribing information.
What is the US approval status of oxymetazoline hydrochloride?
oxymetazoline hydrochloride has approved status in the United States according to our Drugs@FDA-derived records. Verify on the official FDA label before clinical or commercial decisions.